Hansen's Disease (Leprosy)

Current and Future Pharmacotherapy and Treatment of Disease-related Immunologic Reactions

Davey P. Legendre, Pharm.D.; Christina A. Muzny, M.D.; Edwin Swiatlo, M.D., Ph.D.


Pharmacotherapy. 2012;32(1):27-37. 

In This Article

Future Therapy

There is little in terms of novel therapy being explored for future treatment of Hansen's disease, and the same is true for many diseases caused by Mycobacterium species. The diarylquinolone, R207910, is a promising new drug with bactericidal activity comparable to that of moxifloxacin and rifapentine.[59] Its novel mechanism is believed to be inhibition of ATP synthase.[60] In a murine model, R207910 retained bactericidal capabilities even when dosed once/month.[61] Although it must be studied in humans, this drug remains an exciting option for the future.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.